MP4OX: Phase IIa data

In a double-blind, international Phase IIa trial in 51 severely injured trauma patients with lactic acidosis, 250 and 500 mL MP4OX each met the primary endpoint of significantly reducing serum lactate levels from baseline to 2 hours vs. 500 mL of Ringer's lactate solution (p=0.032 for each). Low- and high-dose MP4OX also significantly reduced serum lactate levels from baseline at 1 hour (p=0.028 for each) and at 20 minutes vs. Ringer's lactate solution (p<0.004 for each). ...